Quick answers
- What is Meloxicam used for?
- The FDA-approved label (Meloxicam, Emerald Therapeutics, LLC, May 29, 2026) says: “Meloxicam oral suspension is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older 1.1 Osteoarthritis (OA) Meloxicam oral suspension is indicated for relief of the signs and symptoms of osteoarthritis […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Meloxicam have a boxed warning?
- Yes. The FDA label for Meloxicam has a boxed warning (“WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS”), the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Meloxicam?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Meloxicam been recalled?
- FDA enforcement reports list 2 recalls of products of this medicine; the newest started January 26, 2022 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Meloxicam?
- 45 companies list prescription products of Meloxicam in the FDA NDC Directory, including Advanced Rx of Tennessee, LLC, A-S Medication Solutions and Bryant Ranch Prepack.
What Meloxicam is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Meloxicam oral suspension is a non-steroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older 1.1 Osteoarthritis (OA) Meloxicam oral suspension is indicated for relief of the signs and symptoms of osteoarthritis […]. …
— FDA label: Meloxicam, Emerald Therapeutics, LLC, effective May 29, 2026. Read the full label on DailyMed →
The FDA has 119 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Its heading: WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
. Read it on the full label →
118 of 119 FDA labels for this medicine have a boxed warning.
Forms and how it is given
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| meloxicam 10 mg capsule | Generic | $10.76 per capsule |
| meloxicam 15 mg tablet | Generic | $0.0184 per tablet |
| meloxicam 5 mg capsule | Generic | $8.28 per capsule |
| meloxicam 7.5 mg tablet | Generic | $0.0168 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Advanced Rx of Tennessee, LLC12 products
- A-S Medication Solutions10 products
- Bryant Ranch Prepack10 products
- Aphena Pharma Solutions - Tennessee, LLC9 products
- Remedyrepack Inc.8 products
- PD-Rx Pharmaceuticals, Inc.8 products
- Proficient Rx LP5 products
- XLCare Pharmaceuticals, Inc.4 products
- Asclemed USA, Inc.4 products
- AiPing Pharmaceutical, Inc.4 products
- Preferred Pharmaceuticals Inc.4 products
- Direct_Rx4 products
- Phoenix RX LLC4 products
- Northwind Health Company, LLC4 products
- St. Mary's Medical Park Pharmacy4 products
- NuCare Pharmaceuticals, Inc.4 products
- Lupin Pharmaceuticals, Inc.4 products
- Coupler LLC3 products
- Unichem Pharmaceuticals (USA), Inc.2 products
- Quality Care Products, LLC2 products
- Redpharm Drug2 products
- Quallent Pharmaceuticals Health LLC2 products
- Medcore LLC2 products
- Exelan Pharmaceuticals Inc.2 products
- NCS HealthCare of KY, LLC dba Vangard Labs2 products
- Terrain Pharmaceuticals, Inc.2 products
- Zydus Pharmaceuticals USA Inc.2 products
- ANI Pharmaceuticals, Inc.2 products
- Hawaii Repack, Inc.2 products
- Carlsbad Technology, Inc.2 products
- Aurobindo Pharma Limited2 products
- Cipla USA Inc.2 products
- Camber Pharmaceuticals, Inc.2 products
- Golden State Medical Supply, Inc.2 products
- Chartwell RX, LLC2 products
- AvPAK2 products
- Zydus Lifesciences Limited2 products
- QPharma, Inc.2 products
- Redmont Pharmaceuticals, LLC1 product
- American Health Packaging1 product
- Avondale Pharmaceuticals, LLC1 product
- Emerald Therapeutics, LLC1 product
- Azurity Pharmaceuticals, Inc.1 product
- Nanjing Delova Biotech Co., Ltd.1 product
- Sportpharm LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021530 MELOXICAM | Avondale Pharms | June 1, 2004 | 14, latest November 21, 2024 2024: Labeling · 2021: Labeling · 2016: Labeling |
| NDA217593 QAMZOVA | Nanjing Delova | April 22, 2025 | — |
| NDA218395 XIFYRM | Azurity | June 5, 2025 | — |
Generic approvals (11)
- ANDA077920Aiping Pharm Inc · July 19, 2006
- ANDA077921Zydus Pharms USA · July 19, 2006
- ANDA077929Cipla · July 19, 2006
- ANDA077944Lupin Pharms · July 19, 2006
- ANDA077882Macleods Pharms · July 20, 2006
- ANDA078008Aurobindo Pharma · October 2, 2006
- ANDA077918Yung Shin Pharm · December 7, 2006
- ANDA077927Unichem · December 20, 2006
- ANDA209487Lupin · June 1, 2020
- ANDA211398Novitium Pharma · March 9, 2021
- ANDA217579Ascent Pharms Inc · June 7, 2023
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
January 26, 2022 · Class II · Terminated · D-0190-2024
CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Meloxicam Tablets, USP, 15 mg, 1000 Tablets per bottle, Rx Only, Manufactured by: Cipla Ltd., Kurkumbh, India; Manufactured for: Cipla USA, Inc., 9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156. NDC: 69097-159-15 — CARDINAL HEALTHCARE
-
March 15, 2021 · Class II · Terminated · D-0463-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Meloxicam Tablets, USP 7.5 mg 100 Tablets Rx Only NDC 69097-158-07 Manufactured for: Cipla USA, Inc. 9100 S. Dadeland Blvd., Suite 1500 Miami, FL 33156 — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Meloxicam, Emerald Therapeutics, LLC, effective May 29, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →